Johnson & Johnson (JNJ)

$253.04 +3.07 (1.23%)
Market Cap 594.63B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 23.66
Forward PE 21.92
Profit Margin 28.46%
Debt to Equity Ratio 0.46
Volume 10,072,956
Avg Vol 8,274,148
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 17%
Beta 0.24
Analysts Strong Sell
Price Target $265.44

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
HydrogenH2
HydrogenH2 Jul. 17 at 7:51 PM
$DJT $SPY $JNJ Interesting !! ...We talk about Epstein... Israel & FDA & JNJ baby powder & JFK !! https://www.youtube.com/watch?v=gxoPqY-CgGE
0 · Reply
RarelyRight
RarelyRight Jul. 17 at 6:45 PM
$ATAI Need $JNJ to come off the top rope with a $4.5 Billion all cash offer.
0 · Reply
Millionaire11
Millionaire11 Jul. 17 at 6:39 PM
$CMPS $JNJ acquision coming sooner than we think. Possibly before end of year. Just a prediction
1 · Reply
Tnitty4371
Tnitty4371 Jul. 17 at 5:25 PM
$SPY $DUOL 💵🎁💵🎁 $TSLA $META $JNJ
0 · Reply
Tnitty4371
Tnitty4371 Jul. 17 at 5:18 PM
$SPY 🎁💵🎁💵🎁 we are at the bottom $TSLA $META $QQQ $JNJ
0 · Reply
PrnceMichael
PrnceMichael Jul. 17 at 4:58 PM
$AIMN The right network. The right context. @AimwellBIO Observer connects serious healthcare professionals to trusted signals, curated intelligence, and a verified network built for the future of healthcare. Apply free. Stay in the network. http://aimwellbio.com/observer-signup $AIMN #pharma $PFE $JNJ $MEDI
0 · Reply
TheFrogPrince
TheFrogPrince Jul. 17 at 4:19 PM
$SLS $JNJ Funny to see this rumor being disseminated equal along social media platforms. Wonder who is pushing this, before Dr Sterg goes onto Fox
1 · Reply
DidYouReadThis
DidYouReadThis Jul. 17 at 3:58 PM
$OTLK #Volume #predictions #announcement day? Like if you predict a #tradinghalt on or around #potential #blockbuster #OutlookTherapeutics #PDUFA 7/29/26? #Sup? $JNJ $PFE $UPRO
0 · Reply
FactSheets
FactSheets Jul. 17 at 2:38 PM
$UNH $JNJ $CVX $AMGN 🆕 https://factsheets.com/dogs-of-the-dow-are-rallying-while-the-sp-slides-heres-why/
0 · Reply
Tnitty4371
Tnitty4371 Jul. 17 at 2:17 PM
$TSLA 🎁🎁💵🎁💵🎁 right now iykyk $SPY $META $JNJ
0 · Reply
Latest News on JNJ
Johnson & Johnson upgraded to Buy at Freedom Broker after strong quarter

2026-07-16T17:30:35.000Z - 1 day ago

Johnson & Johnson upgraded to Buy at Freedom Broker after strong quarter

Johnson & Johnson upgraded to Buy from Hold at Freedom Broker

2026-07-16T17:25:12.000Z - 1 day ago

Johnson & Johnson upgraded to Buy from Hold at Freedom Broker

Johnson & Johnson price target raised to $305 from $265 at Scotiabank

2026-07-16T14:15:34.000Z - 1 day ago

Johnson & Johnson price target raised to $305 from $265 at Scotiabank

Johnson & Johnson price target raised to $265 from $258 at Raymond James

2026-07-16T12:50:35.000Z - 1 day ago

Johnson & Johnson price target raised to $265 from $258 at Raymond James

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

Jul 16, 2026, 8:11 AM EDT - 1 day ago

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

DePuy Synthes Acquires Expanding Innovations™

Jul 16, 2026, 8:00 AM EDT - 1 day ago

DePuy Synthes Acquires Expanding Innovations™

Johnson & Johnson price target raised to $282 from $275 at Goldman Sachs

2026-07-16T11:50:11.000Z - 1 day ago

Johnson & Johnson price target raised to $282 from $275 at Goldman Sachs

Johnson & Johnson price target raised to $270 from $260 at JPMorgan

2026-07-16T11:30:25.000Z - 1 day ago

Johnson & Johnson price target raised to $270 from $260 at JPMorgan

Johnson & Johnson price target raised to $294 from $284 at Morgan Stanley

2026-07-16T10:50:21.000Z - 1 day ago

Johnson & Johnson price target raised to $294 from $284 at Morgan Stanley

Johnson & Johnson price target raised to $272 from $263 at Wells Fargo

2026-07-16T10:15:25.000Z - 1 day ago

Johnson & Johnson price target raised to $272 from $263 at Wells Fargo

Johnson & Johnson price target raised to $260 from $250 at Stifel

2026-07-15T19:30:21.000Z - 2 days ago

Johnson & Johnson price target raised to $260 from $250 at Stifel

J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue

Jul 15, 2026, 12:09 PM EDT - 2 days ago

J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue

Johnson & Johnson: Expiration of ACA subsidies won’t impact procedure demand

2026-07-15T13:26:33.000Z - 2 days ago

Johnson & Johnson: Expiration of ACA subsidies won’t impact procedure demand

Johnson & Johnson Stock (JNJ) Falls despite Q2 Beat, Higher Sales Forecast for 2026

2026-07-15T13:18:06.000Z - 2 days ago

Johnson & Johnson Stock (JNJ) Falls despite Q2 Beat, Higher Sales Forecast for 2026

Johnson & Johnson says three of four business units accelerated through Q2

2026-07-15T13:15:12.000Z - 2 days ago

Johnson & Johnson says three of four business units accelerated through Q2

Johnson & Johnson expects operational sales growth to improve in 2H26

2026-07-15T13:11:16.000Z - 2 days ago

Johnson & Johnson expects operational sales growth to improve in 2H26

Johnson & Johnson says capital allocation priorities remain unchanged

2026-07-15T13:00:31.000Z - 2 days ago

Johnson & Johnson says capital allocation priorities remain unchanged

Johnson & Johnson says confident in long term projections of Medtech business

2026-07-15T12:55:17.000Z - 2 days ago

Johnson & Johnson says confident in long term projections of Medtech business

Johnson & Johnson says has strongest portfolio, pipeline in company’s history

2026-07-15T12:45:21.000Z - 2 days ago

Johnson & Johnson says has strongest portfolio, pipeline in company’s history

Johnson & Johnson Earnings Call Transcript: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 2 days ago

Johnson & Johnson Earnings Call Transcript: Q2 2026

Johnson & Johnson Slides: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 2 days ago

Johnson & Johnson Slides: Q2 2026

Johnson & Johnson Earnings release: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 2 days ago

Johnson & Johnson Earnings release: Q2 2026

ASML, Intel, Johnson & Johnson, and More Stocks That Explain Today's Market

Jul 15, 2026, 7:27 AM EDT - 2 days ago

ASML, Intel, Johnson & Johnson, and More Stocks That Explain Today's Market

ASML INTC

Johnson & Johnson Hikes Guidance, Stock Falls

Jul 15, 2026, 6:35 AM EDT - 2 days ago

Johnson & Johnson Hikes Guidance, Stock Falls

Johnson & Johnson Bumps Up Guidance as Sales Rise

Jul 15, 2026, 6:33 AM EDT - 2 days ago

Johnson & Johnson Bumps Up Guidance as Sales Rise

Johnson & Johnson reports Q2 adjusted EPS $2.90, consensus $2.85

2026-07-15T10:26:19.000Z - 2 days ago

Johnson & Johnson reports Q2 adjusted EPS $2.90, consensus $2.85

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

Jul 15, 2026, 6:25 AM EDT - 2 days ago

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Jul 15, 2026, 6:23 AM EDT - 2 days ago

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

Jul 15, 2026, 6:20 AM EDT - 2 days ago

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

The Big 3: UNH, KO, JNJ

Jul 9, 2026, 1:00 PM EDT - 8 days ago

The Big 3: UNH, KO, JNJ

KO UNH

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jul 8, 2026, 7:45 AM EDT - 9 days ago

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jim Cramer says these are the 5 stocks to buy during this market rotation

Jul 6, 2026, 6:29 PM EDT - 10 days ago

Jim Cramer says these are the 5 stocks to buy during this market rotation

PEP SBUX STZ TJX

Healthcare stocks have become a haven for investors ditching tech

Jun 26, 2026, 2:39 PM EDT - 21 days ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE LLY MRNA SNY XBI

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Jun 26, 2026, 12:35 PM EDT - 21 days ago

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jun 25, 2026, 5:00 AM EDT - 22 days ago

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

Jun 15, 2026, 6:00 AM EDT - 4 weeks ago

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 13, 2026, 6:41 AM EDT - 4 weeks ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 13, 2026, 6:33 AM EDT - 4 weeks ago

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Jun 11, 2026, 7:45 AM EDT - 5 weeks ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Jun 11, 2026, 7:14 AM EDT - 5 weeks ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE KYMR

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Jun 11, 2026, 2:03 AM EDT - 5 weeks ago

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Jun 10, 2026, 11:22 AM EDT - 5 weeks ago

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Jun 10, 2026, 6:20 AM EDT - 5 weeks ago

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:00 AM EDT - 5 weeks ago

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Jun 9, 2026, 9:20 AM EDT - 5 weeks ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN LLY MRK NVO PFE

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 9:01 AM EDT - 5 weeks ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:08 AM EDT - 5 weeks ago

Johnson & Johnson to buy Firefly Bio for $1 billion

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Jun 8, 2026, 8:00 AM EDT - 5 weeks ago

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

J&J beats lawsuit alleging that talc caused three women's cancer

Jun 5, 2026, 6:24 PM EDT - 5 weeks ago

J&J beats lawsuit alleging that talc caused three women's cancer

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Jun 3, 2026, 12:04 AM EDT - 6 weeks ago

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

SLE

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

Jun 3, 2026, 12:03 AM EDT - 6 weeks ago

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification

Jun 2, 2026, 6:24 PM EDT - 6 weeks ago

Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification

JPM KMB MCD YUM

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

May 31, 2026, 8:39 AM EDT - 6 weeks ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

May 31, 2026, 8:29 AM EDT - 6 weeks ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

May 31, 2026, 8:27 AM EDT - 6 weeks ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

May 31, 2026, 8:01 AM EDT - 6 weeks ago

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

May 29, 2026, 2:00 PM EDT - 7 weeks ago

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

May 29, 2026, 8:18 AM EDT - 7 weeks ago

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

May 28, 2026, 7:10 PM EDT - 7 weeks ago

FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

May 28, 2026, 5:30 AM EDT - 7 weeks ago

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

May 27, 2026, 4:22 PM EDT - 7 weeks ago

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

Johnson & Johnson Transcript: Bernstein 42nd Annual Strategic Decisions Conference

May 27, 2026, 11:00 AM EDT - 7 weeks ago

Johnson & Johnson Transcript: Bernstein 42nd Annual Strategic Decisions Conference

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

May 21, 2026, 7:00 AM EDT - 2 months ago

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

Johnson & Johnson says nipocalimab approved in China

May 21, 2026, 4:31 AM EDT - 2 months ago

Johnson & Johnson says nipocalimab approved in China

Johnson & Johnson Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 11:30 AM EDT - 2 months ago

Johnson & Johnson Transcript: RBC Capital Markets Global Healthcare Conference 2026

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

May 19, 2026, 9:00 AM EDT - 2 months ago

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

May 14, 2026, 4:01 PM EDT - 2 months ago

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

STGW

Johnson & Johnson Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 2:20 PM EDT - 2 months ago

Johnson & Johnson Transcript: Bank of America Global Healthcare Conference 2026

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

May 12, 2026, 7:45 AM EDT - 2 months ago

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 11, 2026, 4:34 PM EDT - 2 months ago

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

May 11, 2026, 8:00 AM EDT - 2 months ago

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J

May 7, 2026, 11:34 AM EDT - 2 months ago

This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J

MO

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

May 7, 2026, 8:00 AM EDT - 2 months ago

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

CVS to drop J&J's Stelara from its main formularies

May 5, 2026, 9:15 AM EDT - 2 months ago

CVS to drop J&J's Stelara from its main formularies

CVS

HydrogenH2
HydrogenH2 Jul. 17 at 7:51 PM
$DJT $SPY $JNJ Interesting !! ...We talk about Epstein... Israel & FDA & JNJ baby powder & JFK !! https://www.youtube.com/watch?v=gxoPqY-CgGE
0 · Reply
RarelyRight
RarelyRight Jul. 17 at 6:45 PM
$ATAI Need $JNJ to come off the top rope with a $4.5 Billion all cash offer.
0 · Reply
Millionaire11
Millionaire11 Jul. 17 at 6:39 PM
$CMPS $JNJ acquision coming sooner than we think. Possibly before end of year. Just a prediction
1 · Reply
Tnitty4371
Tnitty4371 Jul. 17 at 5:25 PM
$SPY $DUOL 💵🎁💵🎁 $TSLA $META $JNJ
0 · Reply
Tnitty4371
Tnitty4371 Jul. 17 at 5:18 PM
$SPY 🎁💵🎁💵🎁 we are at the bottom $TSLA $META $QQQ $JNJ
0 · Reply
PrnceMichael
PrnceMichael Jul. 17 at 4:58 PM
$AIMN The right network. The right context. @AimwellBIO Observer connects serious healthcare professionals to trusted signals, curated intelligence, and a verified network built for the future of healthcare. Apply free. Stay in the network. http://aimwellbio.com/observer-signup $AIMN #pharma $PFE $JNJ $MEDI
0 · Reply
TheFrogPrince
TheFrogPrince Jul. 17 at 4:19 PM
$SLS $JNJ Funny to see this rumor being disseminated equal along social media platforms. Wonder who is pushing this, before Dr Sterg goes onto Fox
1 · Reply
DidYouReadThis
DidYouReadThis Jul. 17 at 3:58 PM
$OTLK #Volume #predictions #announcement day? Like if you predict a #tradinghalt on or around #potential #blockbuster #OutlookTherapeutics #PDUFA 7/29/26? #Sup? $JNJ $PFE $UPRO
0 · Reply
FactSheets
FactSheets Jul. 17 at 2:38 PM
$UNH $JNJ $CVX $AMGN 🆕 https://factsheets.com/dogs-of-the-dow-are-rallying-while-the-sp-slides-heres-why/
0 · Reply
Tnitty4371
Tnitty4371 Jul. 17 at 2:17 PM
$TSLA 🎁🎁💵🎁💵🎁 right now iykyk $SPY $META $JNJ
0 · Reply
WallStJesus
WallStJesus Jul. 17 at 1:51 PM
SELECT EARLY BULL FLOW INTO THE WEAKNESS = $LLY $JNJ $UNH $GE $XLF
0 · Reply
profit_guru
profit_guru Jul. 17 at 1:10 PM
$JNJ - might rally above 260 on rotation from tech to healthcare
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 17 at 12:59 PM
$ELTP $GME $JNJ $BTC.X $WEN Elite Pharmaceuticals Inc. ($ELTP) jumped 6.43% yesterday, closing at $0.399 per share The Rally will continue today. Hold on people. Its all about SequestOx. Check it out. The News is leaking....... The specialty generic drug manufacturer saw a strong late-day push, hitting an intraday high of $0.3997.FINANCIAL Backdrop: Momentum follows a massive fiscal year 2026 revenue surge of 77% to $149 million, driven by commercial rollouts like generic Vyvanse and its new Methadone launch.Growth Ahead: Investors are eying upcoming catalysts, including a scheduled product launch next month for Ropinirole and a strong pipeline of pending abbreviated new drug applications (ANDAs)
1 · Reply
LiveTradePro
LiveTradePro Jul. 17 at 12:33 PM
$JNJ Gap up today by the look
0 · Reply
TheGhostOfQuentc
TheGhostOfQuentc Jul. 17 at 12:31 PM
$SPY $MRK $JNJ It looks like Mannkind is going to get another blockbuster-potential product FDA approved soon. Holders of MNKD shares should make out nicely on the news.
0 · Reply
profit_guru
profit_guru Jul. 17 at 5:44 AM
$MDT - $JNJ Rotation back to health care and dividend stocks tomorrow…algos will might rally $MDT above 86 ..too cheap at these levels
0 · Reply
TNNStockAnalysisNews
TNNStockAnalysisNews Jul. 17 at 3:00 AM
Top Stock Gainers Today (Wednesday, July 16, 2026) $CMPS – +7% $JNJ – +1.61% $NVDA $CSCO $LLY https://truthsandnews.com/markets/top-stock-gainers-today-july-16-2026-abbott-ataibeckley
0 · Reply
Prady
Prady Jul. 17 at 2:06 AM
$BSX $JNJ Will buy Boston's scientific soon
1 · Reply
LiveTradePro
LiveTradePro Jul. 17 at 12:46 AM
$JNJ Reversal potential https://share.trendspider.com/chart/JNJ/6682o7wivo
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Jul. 17 at 12:40 AM
$JNJ should continue rally targeting 271.37 or higher within daily bull run against May-2026 low. Short term pullback against 6.22.2026 low should remain supported to continue rally to extend ((5)). Check out the details at https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ
0 · Reply
parcha
parcha Jul. 16 at 11:33 PM
$GE $WFC $JNJ $UNH CNBC’s Jim Cramer said Wall Street unfairly punished several companies despite delivering strong earnings. He highlighted GE Aerospace, Wells Fargo, Johnson & Johnson, Levi’s, and UnitedHealth as buying opportunities. https://www.cnbc.com/2026/07/16/jim-cramer-stocks-wall-street-got-wrong.html
0 · Reply
spearnreel
spearnreel Jul. 16 at 9:17 PM
$ISRG Numbers across the board are great. Excellent margins. Growth still maintained but perhaps not enough to award such a premium when compared within the sector? $BSX $MDT $ABT All med tech including $JNJ releasing record numbers this week already. Same here. Orchestrated buying op imo.
0 · Reply